Back to search
FDAFDA · Food and drugs·Recall number D-0869-2023

Buprenorphine Sublingual Tablets, 8 mg, 30 count-bottles, Rx only, Manufactured by: Sun Pharma, NDC 62756-460-83.

Published June 14, 2023 · Recall initiated: May 3, 2023

Summary

FDA records drug Class II recall D-0869-2023, published June 14, 2023 and initiated May 3, 2023. Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC; Status: Terminated; Reported quantity: 12,336 bottles; Lot: Lot #: DND1515A, Exp 08/24. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email if BUPRENORPHINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
BUPRENORPHINE
Manufacturer
SUN PHARMACEUTICAL INDUSTRIES INC
Distributor
Product was distributed to 19 distributors nationwide.
Lot
Lot #: DND1515A, Exp 08/24
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Buprenorphine Sublingual Tablets, 8 mg, 30 count-bottles, Rx only, Manufactured by: Sun Pharma, NDC 62756-460-83. recalled?

Yes. FDA published recall D-0869-2023 on June 14, 2023. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: BUPRENORPHINE.